{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T17:01:16Z","timestamp":1792515676394,"version":"4.5.0"},"reference-count":36,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2019,5,1]],"date-time":"2019-05-01T00:00:00Z","timestamp":1556668800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,5,1]],"date-time":"2019-05-01T00:00:00Z","timestamp":1556668800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","gynecologiconcology-online.net","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Gynecologic Oncology"],"published-print":{"date-parts":[[2019,5]]},"DOI":"10.1016\/j.ygyno.2019.03.003","type":"journal-article","created":{"date-parts":[[2019,3,18]],"date-time":"2019-03-18T01:03:33Z","timestamp":1552871013000},"page":"326-334","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":31,"title":["Retrospective study of a 16\u202fyear cohort of BRCA1 and BRCA2 carriers presenting for RRSO: Prevalence of invasive and in-situ carcinoma, with follow-up"],"prefix":"10.1016","volume":"153","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1365-3452","authenticated-orcid":false,"given":"F.","family":"Blok","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1804-5015","authenticated-orcid":false,"given":"S.","family":"Dasgupta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"W.N.M.","family":"Dinjens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.M.","family":"Roes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H.J.","family":"van Beekhuizen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1779-1115","authenticated-orcid":false,"given":"P.C.","family":"Ewing-Graham","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ygyno.2019.03.003_bb0005","doi-asserted-by":"crossref","unstructured":"L.A. Torre, F. Bray, R.L. Siegel, et al. Global cancer statistics 2012. CA Cancer J. Clin.. 65 (2015) 87\u2013108. doi: https:\/\/doi.org\/10.3322\/caac.21262.","DOI":"10.3322\/caac.21262"},{"key":"10.1016\/j.ygyno.2019.03.003_bb0010","doi-asserted-by":"crossref","unstructured":"K.B. Kuchenbaecker, J.L. Hopper, D.R. Barnes, et al. Risks of breast, ovarian, and contralateral breast cancer for BRCA1 and BRCA2 mutation carriers. JAMA 317 (2017) 2402\u20132416. doi: https:\/\/doi.org\/10.1001\/jama.2017.7112.","DOI":"10.1001\/jama.2017.7112"},{"key":"10.1016\/j.ygyno.2019.03.003_bb0015","series-title":"Genetic\/Familial High-Risk Assessment: Breast and Ovarian. NCNN Clinical Practice Guidelines in Oncology V12013","author":"National Comprehensive Cancer Network","year":"2013"},{"key":"10.1016\/j.ygyno.2019.03.003_bb0020","doi-asserted-by":"crossref","unstructured":". S.M. Domchek, T.M. Friebel, C.F. Singer, et al. Association of risk-reducing surgery in BRCA1 or BRCA2 mutation carriers with cancer risk and mortality. JAMA. 304 (2010) 967\u2013975.","DOI":"10.1001\/jama.2010.1237"},{"key":"10.1016\/j.ygyno.2019.03.003_bb0025","doi-asserted-by":"crossref","unstructured":"J.M. Piek, P.J. van Diest, R.P. Zweemer, et al. Dysplastic changes in prophylactically removed fallopian tubes of women predisposed to developing ovarian cancer. J. Pathol. 195 (2001) 451\u2013456.","DOI":"10.1002\/path.1000"},{"key":"10.1016\/j.ygyno.2019.03.003_bb0030","doi-asserted-by":"crossref","unstructured":"F. Medeiros, M.G. Muto, Y. Lee, et al. The tubal fimbria is a preferred site for early adenocarcinoma in women with familial ovarian cancer syndrome. Am. J. Surg. Pathol. 30 (2006) 230\u2013236.","DOI":"10.1097\/01.pas.0000180854.28831.77"},{"key":"10.1016\/j.ygyno.2019.03.003_bb0035","doi-asserted-by":"crossref","unstructured":". S.L. Wethington, K.J. Park, R.A. Soslow, et al. Clinical outcome of isolated serous tubal intraepithelial neoplasia (STIC). Int. J. Gynecol. Cancer 23 (2013) 1603\u20131611. doi: https:\/\/doi.org\/10.1097\/IGC.0b013e3182a80ac8.","DOI":"10.1097\/IGC.0b013e3182a80ac8"},{"key":"10.1016\/j.ygyno.2019.03.003_bb0040","doi-asserted-by":"crossref","unstructured":"C.P. Crum, R. Drapkin, A. Miron, et al. The distal fallopian tube: a new model for pelvic serous carcinogenesis. Curr Opin Obstet Gynecol. 19 (2007) 3\u20139.","DOI":"10.1097\/GCO.0b013e328011a21f"},{"key":"10.1016\/j.ygyno.2019.03.003_bb0045","doi-asserted-by":"crossref","unstructured":"J.C. Morrison, L.Z. Blanco, R. Vang, et al. Incidental serous tubal intraepithelial carcinoma and early invasive serous carcinoma in the nonprophylactic setting: analysis of a case series. Am. J. Surg. Pathol.. 39 (2015) 442\u2013453. doi: https:\/\/doi.org\/10.1097\/PAS.0000000000000352.","DOI":"10.1097\/PAS.0000000000000352"},{"key":"10.1016\/j.ygyno.2019.03.003_bb0050","doi-asserted-by":"crossref","unstructured":"D.R. Nebgen, J. Hurteau, L.L. Holman, et al. Bilateral salpingectomy with delayed oophorectomy for ovarian cancer risk reduction: a pilot study in women with BRCA1\/2 mutations. Gynecol. Oncol. 150 (2018) 79\u201384. doi: https:\/\/doi.org\/10.1016\/j.ygyno.2018.04.564.","DOI":"10.1016\/j.ygyno.2018.04.564"},{"key":"10.1016\/j.ygyno.2019.03.003_bb0055","doi-asserted-by":"crossref","unstructured":". M.G Harmsen, M. Arts-de Jong M, N. Hoogerbrugge, et al. Early salpingectomy (TUbectomy) with delayed oophorectomy to improve quality of life as alternative for risk-reducing salpingo-oophorectomy in BRCA1\/2 mutation carriers (TUBAstudy): a prospective non-randomised multicentre study. BMC Cancer. (2015)15:593. doi: https:\/\/doi.org\/10.1186\/s12885-015-1597-y.","DOI":"10.1186\/s12885-015-1597-y"},{"key":"10.1016\/j.ygyno.2019.03.003_bb0060","doi-asserted-by":"crossref","unstructured":". E. Leblanc E, F. Narducci, I. Farre, et al. Radical fimbriectomy: a reasonable temporary risk-reducing surgery for selected women with a germ line mutation of BRCA 1 or 2 genes? Rationale and preliminary development. Gynecol. Oncol. 121 (2011) 472\u20136. doi: https:\/\/doi.org\/10.1016\/j.ygyno.2011.02.012.","DOI":"10.1016\/j.ygyno.2011.02.012"},{"key":"10.1016\/j.ygyno.2019.03.003_bb0080","unstructured":". METC Code Non-WMO Research. Central committee on research involving human subjects; [19th of March 2016]; Available from: http:\/\/www.ccmo.nl. Last accessed February, 2019."},{"key":"10.1016\/j.ygyno.2019.03.003_bb0085","doi-asserted-by":"crossref","unstructured":"Y. Lee, F. Medeiros, D. Kindelberger, et al. Advances in the recognition of tubal intraepithelial carcinoma: applications to cancer screening and the pathogenesis of ovarian cancer. Adv. Anat. Pathol.. 13 (2006) 1\u20137.","DOI":"10.1097\/01.pap.0000201826.46978.e5"},{"key":"10.1016\/j.ygyno.2019.03.003_bb0090","doi-asserted-by":"crossref","unstructured":". N. Singh, C.B. Gilks, L. Hirschowitz, et al. Primary site assignment in tubo-ovarian high-grade serous carcinoma: consensus statement on unifying practice worldwide. Gynecol. Oncol. 141 (2016) 196\u2013198. doi: https:\/\/doi.org\/10.1016\/j.ygyno.2015.","DOI":"10.1016\/j.ygyno.2015.10.022"},{"key":"10.1016\/j.ygyno.2019.03.003_bb0095","doi-asserted-by":"crossref","unstructured":". H.J. Dubbink, P.N. Atmodimedjo, R. van Marion, et al. Diagnostic detection of allelic losses and imbalances by next-generation sequencing 1p\/19q co-deletion analysis of gliomas. J Mol Diagn. 18 (2016) 775\u2013786. doi: https:\/\/doi.org\/10.1016\/j.jmoldx.2016.06.002.","DOI":"10.1016\/j.jmoldx.2016.06.002"},{"key":"10.1016\/j.ygyno.2019.03.003_bb0100","doi-asserted-by":"crossref","unstructured":"M.G. Harmsen, J.M.J. Piek, J. Bulten,et al. Peritoneal carcinomatosis after risk-reducing surgery in BRCA1\/2 mutation carriers. Cancer. 124 (2018) 952\u2013959. doi: https:\/\/doi.org\/10.1002\/cncr.31211.","DOI":"10.1002\/cncr.31211"},{"key":"10.1016\/j.ygyno.2019.03.003_bb0105","doi-asserted-by":"crossref","unstructured":"N.M.A. Van der Hoeven, K. Van Wijk, S.E. Bonfrer, et al. Outcome and prognostic impact of surgical staging in serous tubal intraepithelial carcinoma: a cohort study and systematic review. Clin Oncol (R Coll Radiol). 30 (2018) 463\u2013471. doi: https:\/\/doi.org\/10.1016\/j.clon.2018.03.036.","DOI":"10.1016\/j.clon.2018.03.036"},{"key":"10.1016\/j.ygyno.2019.03.003_bb0110","doi-asserted-by":"crossref","DOI":"10.3802\/jgo.2017.28.e3","article-title":"Pathologic findings at risk-reducing salpingo-oophorectomy (RRSO) in germline BRCA mutation carriers with breast cancer: significance of bilateral RRSO at the optimal age in germline BRCA mutation carriers","volume":"28","author":"Lee","year":"2017","journal-title":"J. Gynecol. Oncol."},{"key":"10.1016\/j.ygyno.2019.03.003_bb0115","doi-asserted-by":"crossref","unstructured":"C. Garcia, J. Wendt, L. Lyon, et al. Risk management options elected by women after testing positive for a BRCA mutation. Gynecol. Oncol. 132 (2014) 428\u2013433. doi: https:\/\/doi.org\/10.1016\/j.ygyno.2013.12.014.","DOI":"10.1016\/j.ygyno.2013.12.014"},{"key":"10.1016\/j.ygyno.2019.03.003_bb0120","doi-asserted-by":"crossref","unstructured":". J.R. Connor, E. Meserve, E. Pizer, et al. Outcome of unexpected adnexal neoplasia discovered during risk reduction salpingo-oophorectomy in women with germ-line BRCA1 or BRCA2 mutations. Gynecol. Oncol.. 132 (2014) 280\u2013286. doi: https:\/\/doi.org\/10.1016\/j.ygyno.2013.","DOI":"10.1016\/j.ygyno.2013.12.009"},{"key":"10.1016\/j.ygyno.2019.03.003_bb0125","doi-asserted-by":"crossref","unstructured":"R. Manchanda, A. Abdelraheim, M. Johnson, et al. Outcome of risk-reducing salpingo-oophorectomy in BRCA carriers and women of unknown mutation status. BJOG 118 (2011) 814\u2013824. doi: https:\/\/doi.org\/10.1111\/j.1471-0528.2011.02920.x.","DOI":"10.1111\/j.1471-0528.2011.02920.x"},{"key":"10.1016\/j.ygyno.2019.03.003_bb0130","doi-asserted-by":"crossref","unstructured":". A. Finch A, M. Beiner, J. Lubinski, et al. Salpingo-oophorectomy and the risk of ovarian, fallopian tube, and peritoneal cancers in women with a BRCA1 or BRCA2 mutation. JAMA. 296 (2006) 185\u2013192.","DOI":"10.1001\/jama.296.2.185"},{"key":"10.1016\/j.ygyno.2019.03.003_bb0135","doi-asserted-by":"crossref","unstructured":"J.D. Lamb, R.L. Garcia, B.A. Goff, et al. Predictors of occult neoplasia in women undergoing risk-reducing salpingo-oophorectomy. Am. J. Obstet. Gynecol. 194 (2006) 1702\u20131709.","DOI":"10.1016\/j.ajog.2006.03.006"},{"key":"10.1016\/j.ygyno.2019.03.003_bb0140","doi-asserted-by":"crossref","unstructured":"W. Reitsma, G.H. de Bock, J.C. Oosterwijk, et al. Support of the fallopian tube hypothesis; in a prospective series of risk-reducing salpingo-oophorectomy specimens. Eur. J. Cancer. 49 (2013) 132\u2013141. doi: https:\/\/doi.org\/10.1016\/j.ejca.2012.07.021.","DOI":"10.1016\/j.ejca.2012.07.021"},{"key":"10.1016\/j.ygyno.2019.03.003_bb0145","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1016\/j.ygyno.2014.01.018","article-title":"Risk reducing salpingo-oophorectomy for BRCA mutation carriers: twenty years later","volume":"132","author":"Powell","year":"2014","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.ygyno.2019.03.003_bb0150","doi-asserted-by":"crossref","unstructured":". J.R. Connor, E. Meserve, E. Pizer, J. Garber, M. Roh, N. Urban et al. Outcome of unexpected adnexal neoplasia discovered during risk reduction salpingooophorectomy in women with germ-line BRCA1 or BRCA2 mutations. Gynecol. Oncol. 2 (2014) 280\u20136.","DOI":"10.1016\/j.ygyno.2013.12.009"},{"key":"10.1016\/j.ygyno.2019.03.003_bb0155","doi-asserted-by":"crossref","unstructured":". M.J. Mingels, T. Roelofsen, J.A. van der Laak, J.A. de Hullu JA, M.A. van Ham, L.F. Massuger, et al. Tubal epithelial lesions in salpingo-oophorectomy specimens of BRCA-mutation carriers and controls. Gynecol. Oncol. 127 (2012) 88\u201393.","DOI":"10.1016\/j.ygyno.2012.06.015"},{"key":"10.1016\/j.ygyno.2019.03.003_bb0160","doi-asserted-by":"crossref","unstructured":"M. Zakhour, Y. Danovitch, J. Lester, B.J. Rimel, C.S. Walsh, A.J. Li, et al. Occult and subsequent cancer incidence following risk-reducing surgery in BRCA mutation carriers. Gynecol. Oncol. 143 (2016) 231\u2013235.","DOI":"10.1016\/j.ygyno.2016.08.336"},{"key":"10.1016\/j.ygyno.2019.03.003_bb0165","doi-asserted-by":"crossref","DOI":"10.1111\/1471-0528.15651","article-title":"Risk reducing early salpingectomy and delayed oophorectomy as a two staged alternative for primary prevention of ovarian cancer in increased risk women: a commentary","author":"Gaba","year":"2019","journal-title":"BJOG"},{"key":"10.1016\/j.ygyno.2019.03.003_bb0170","doi-asserted-by":"crossref","unstructured":"M.G. Patrono, C. Corzo, M. Iniesta, et al. Management of preinvasive lesions. Clin. Obstet. Gynecol.. 60 (2017) 771\u2013779. doi: https:\/\/doi.org\/10.1097\/GRF.0000000000000316.","DOI":"10.1097\/GRF.0000000000000316"},{"key":"10.1016\/j.ygyno.2019.03.003_bb0175","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/j.gore.2015.03.007","article-title":"Low grade serous carcinoma of the peritoneum in a BRCA1 carrier previously diagnosed with a \u201clow-grade serous tubal intra-epithelial carcinoma\u201d (STIC) on risk reducing surgery","volume":"12","author":"Chay","year":"2015","journal-title":"Gynecologic Oncology Reports"},{"key":"10.1016\/j.ygyno.2019.03.003_bb0180","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1038\/modpathol.2016.238","article-title":"Serous tubal intraepithelial neoplasia: the concept and its application","volume":"30","author":"Meserve","year":"2017","journal-title":"Mod. Pathol."},{"key":"10.1016\/j.ygyno.2019.03.003_bb0185","doi-asserted-by":"crossref","unstructured":"T.R. Soong, B.E. Howitt, A. Miron, N.S. Horowitz, F. Campbell, C.M. Feltmate et al. Evidence for lineage continuity between early serous proliferations (ESPs) in the fallopian tube and disseminated high-grade serous carcinomas. J. Pathol. 246 (2018) 344\u2013351.","DOI":"10.1002\/path.5145"},{"key":"10.1016\/j.ygyno.2019.03.003_bb0190","doi-asserted-by":"crossref","unstructured":"S. Intidhar Labidi-Galy, E. Papp, D. Hallberg, N. Niknafs, V. Adleff, M. Noe, R. Bhattacharya et al. High grade serous ovarian carcinomas originate in the fallopian tube. Nat. Commun. 23 (2017):1093.","DOI":"10.1038\/s41467-017-00962-1"},{"key":"10.1016\/j.ygyno.2019.03.003_bb0195","doi-asserted-by":"crossref","unstructured":"K. Suda, H. Nakaoka, C. Hata, N. Yahata, M. Isobe, H. Kameyama et al. Concurrent isolated retroperitoneal HGSC and STIC defined by somatic mutation analysis: a case report. Diagn. Pathol. (2019) 14:17.","DOI":"10.1186\/s13000-019-0795-3"}],"container-title":["Gynecologic Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090825819301519?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090825819301519?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,25]],"date-time":"2025-09-25T03:46:59Z","timestamp":1758772019000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0090825819301519"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,5]]},"references-count":36,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2019,5]]}},"alternative-id":["S0090825819301519"],"URL":"https:\/\/doi.org\/10.1016\/j.ygyno.2019.03.003","relation":{},"ISSN":["0090-8258"],"issn-type":[{"value":"0090-8258","type":"print"}],"subject":[],"published":{"date-parts":[[2019,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Retrospective study of a 16\u202fyear cohort of BRCA1 and BRCA2 carriers presenting for RRSO: Prevalence of invasive and in-situ carcinoma, with follow-up","name":"articletitle","label":"Article Title"},{"value":"Gynecologic Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ygyno.2019.03.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}